Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ALNY

Alnylam Pharmaceuticals Inc

May 15 • 10:10AM ET

289.30

-4.15 -1.41 %

Healthcare • Biotechnology • USA • Large • NASD

Peers: ARWR SRPT BMRN RARE REGN VRTX MRNA BNTX UTHR EXEL

| Held by: VTI VO QQQ VUG VXF VOT IBB IWP CGGR QQQM

Scroll to Statements

Index	NDX	P/E	68.74	EPS (ttm)	4.21	Insider Own	0.69%	Shs Outstand	133.44M	Perf Week	-1.95%
Market Cap	38.63B	Forward P/E	27.17	EPS next Y	10.65	Insider Trans	-8.75%	Shs Float	132.59M	Perf Month	-9.63%
Enterprise Value	38.59B	PEG	0.35	EPS next Q	1.61	Inst Own	96.15%	Short Float	3.60%	Perf Quarter	-7.98%
Income	577.22M	P/S	9.01	EPS this Y	217.25%	Inst Trans	-1.53%	Short Ratio	4.24	Perf Half Y	-36.10%
Sales	4.29B	P/B	35.90	EPS next Y	44.02%	ROA	12.36%	Short Interest	4.77M	Perf YTD	-27.25%
Book/sh	8.06	P/C	12.84	EPS next 5Y	78.62%	ROE	96.94%	52W High	495.55 -41.62%	Perf Year	2.08%
Cash/sh	22.54	P/FCF	60.23	EPS past 3/5Y	- -	ROIC	15.30%	52W Low	266.18 8.69%	Perf 3Y	40.30%
Dividend Est.	-	EV/EBITDA	47.82	Sales past 3/5Y	52.98% 49.77%	Gross Margin	80.83%	Volatility	3.31% 3.76%	Perf 5Y	113.19%
Dividend TTM	-	EV/Sales	9.00	EPS Y/Y TTM	308.45%	Oper. Margin	17.54%	ATR (14)	11.20	Perf 10Y	450.52%
Dividend Ex-Date	-	Quick Ratio	3.06	Sales Y/Y TTM	82.57%	Profit Margin	13.46%	RSI (14)	39.09	Recom	1.76
Dividend Gr. 3/5Y	- -	Current Ratio	3.13	EPS Q/Q	440.32%	SMA20	-3.74%	Beta	0.28	Target Price	445.36
Payout	0.00%	Debt/Eq	2.76	Sales Q/Q	96.43%	SMA50	-7.54%	Rel Volume	0.64	Prev Close	293.45
Employees	2500	LT Debt/Eq	2.51	Earnings	Apr 30 BMO	SMA200	-26.06%	Avg Volume	1.13M	Price	289.30
IPO	May 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	73.26% 4.63%	Trades		Volume	105,992	Change	-1.41%

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)